Atea Pharmaceuticals, Inc.
NASDAQ:AVIRBiotechnology
-$0.04 today
- Market cap
- $320.41M
- Beta
- 0.32
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$2.14
Volume 0.34M
Average 0.34M
AVIR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Atea Pharmaceuticals, Inc.NASDAQ: AVIR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $45.44M (cash outflow) rose 32.6% year over year, ahead of the +21.5% change in trailing-twelve-month net income. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$141.23M (-10.8%) for the fiscal year ending Dec 2026, a slowdown from the -6.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$45.44M+1.3% QoQ
- Last fiscal yearDec 2025
- -$158.35M-6.0% YoY
- LTMMar 2026
- -$169.52M+21.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.6% | +19.8% | -12.8 pp |
| 1 year | -6.0% | -10.8% | -4.9 pp |
| 3-year CAGR | +11.0% | -12.3% | -23.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (158.35M) USD
- Year-over-year change
- +6.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (158.35M) | +6.0% |
| FY2024 | 2024-12-31 | (168.39M) | -23.9% |
| FY2023 | 2023-12-31 | (135.96M) | -17.3% |
| FY2022 | 2022-12-31 | (115.91M) | -195.6% |
| FY2021 | 2021-12-31 | 121.19M | — |
Net Income vs competitors
How AVIR compares with its peers on the latest reported figures
- AVIR's LTM Mar 2026 net income of $169.52M is the 2nd largest of the 5 companies compared; the peer median is $34.18M.
- Its year-over-year change of +21.5% is the 2nd highest of 5, against a peer median of -29.5%.
- Over three fiscal years its annual growth of +11.0% compares with a peer median of -21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $442.72M | -23.4% | — | 676.0% | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $160.72M | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding AVIR) | $34.18M | -29.5% | -21.6% | 86.8% | |
Competitors are the stored peer set for AVIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 121.19M | (115.91M) | (135.96M) | (168.39M) | (158.35M) |
| Depreciation & Amortization | 29K | 260K | 416K | 416K | 416K |
| Deferred Income Tax | (29.39M) | 0 | (48.56M) | 0 | (6.36M) |
| Stock-Based Compensation | 39.62M | 46.72M | 49.43M | 51.77M | 20.72M |
| Change in Working Capital | (247.85M) | (46.59M) | 16.16M | (7.48M) | 16.48M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10.29M | (1.98M) | 1.7M | 206K | 8.49M |
| Other Working Capital | (258.13M) | (44.6M) | 14.46M | (7.68M) | 8M |
| Other Non-Cash Items | 29.39M | (5.47M) | 33.11M | (11.82M) | (4.94M) |
| Operating Cash Flow | (87.01M) | (120.98M) | (85.4M) | (135.5M) | (132.03M) |
| Capital Expenditures | (4K) | (1.94M) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 453.47K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (545.35M) | (562.36M) | (461.18M) | (281.94M) |
| Sales of Investments | 0 | 91.89M | 602.67M | 517.28M | 470.73M |
| Other Investing Activities | 0 | (453.47K) | 0 | 0 | 0 |
| Investing Cash Flow | (4K) | (455.41M) | 40.3M | 56.11M | 188.79M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.47M | 230K | 257K | 267K | 259K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (25.52M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 140K | 0 | 0 | (485K) |
| Financing Cash Flow | 1.47M | 370K | 257K | 267K | (25.75M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (85.54M) | (576.02M) | (44.84M) | (79.13M) | 31.02M |
| Free Cash Flow | (87.01M) | (122.93M) | (85.4M) | (135.5M) | (132.03M) |
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
Intrinsic Alpha fair value
Locked
Current Price
$3.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.